No. | Groups | % Killing (mean ± SD) |
---|---|---|
1 | Control (L3 + PBMCs) | 0 |
2 | NEN (L3 + PBMCs + Pooled NEN sera) | 9.7 ± 4.0 |
3 | EN (L3 + PBMCs + Pooled EN sera) | 84.1 ± 3.6a |
4 | L3 + PBMCs + anti Bm-TPP antibodies depleted Pooled EN sera | 30.2 ± 3.0b |
5 | L3 + PBMCs + anti BmAF-Myo antibodies depleted Pooled EN sera | 51.1 ± 1.9 |
6 | L3 + PBMCs + anti Wol Tl IF-1 antibodies depleted Pooled EN sera | 47.6 ± 4.1 |
7 | L3 + PBMCs + anti wBm-LigA antibodies depleted Pooled EN sera | 29.4 ± 4.2b |
8 | MF (L3 + PBMCs + Pooled MF sera) | 31.5 ± 1.6 |
9 | L3 + PBMCs + anti Bm-TPP antibodies depleted Pooled MF sera | 21.8 ± 1.6 |
10 | L3 + PBMCs + anti BmAF-Myo antibodies depleted Pooled MF sera | 22.9 ± 4.9 |
11 | L3 + PBMCs + anti Wol Tl IF-1 antibodies depleted Pooled MF sera | 23.9 ± 3.4 |
12 | L3 + PBMCs + anti wBm-LigA antibodies depleted Pooled MF sera | 22.7 ± 3.5 |
13 | CP (L3 + PBMCs + Pooled CP sera) | 35.0 ± 3.6 |
14 | L3 + PBMCs + anti Bm-TPP antibodies depleted Pooled CP sera | 23.4 ± 1.4 |
15 | L3 + PBMCs + anti BmAF-Myo antibodies depleted Pooled CP sera | 27.8 ± 2.9 |
16 | L3 + PBMCs + anti Wol Tl IF-1 antibodies depleted Pooled CP sera | 22.1 ± 2.6b |
17 | L3 + PBMCs + anti wBm-LigA antibodies depleted Pooled CP sera | 24.9 ± 1.8 |